newsfilter
← Latest News
Earnings Call Transcripts·

Stephens Annual Investment Conference - NEOGENOMICS INC

We'll go ahead and get started here. Welcome to day one of the Stevens Conference. I'm Mason Carrico. I'm the Diagnostics and MedTech Analyst here. Happy to have the NEO team with us here today. We've got Tony Zook, CEO, Warren Stone, COO, soon-to-be CEO, Navichek Jain, CFO. First, thank you guys for being here. Cheers. Maybe to start off, just give us a quick overview of Q3, main takeaways, highlights, what we should be thinking about coming out of the print. Yeah, I'll kick us off, and if I miss anything, Warren and Abishak can jump in. I would say, Mason, all in all, it was a really strong quarter for us, Q3 as we head into Q4. You know, our clinical business, which makes up about 93% of our business, that was up 13%. It was driven in large part by NGS, right? our NGS business, which I think is probably still not a well-appreciated part of the NEO story. It's a third of our business and it grew 29%, right? So that's a business that's, you know, $250 million growing at a really nice clip. That in turn helped contribute, you know, because of volume. That 29% was driven by 17% volume growth. So very durable performance on the NGS side. In our large panels, we're also up over 25%. And so when we look consistently across the NGS portfolio, we see really good underlying trends there. Our AUP was what we thought would be slightly higher, in fact, up at around 11%. So we always thought we could get, you know, upper single digit. So we beat those expectations for ourselves. We initiated the rollout in MRD for our IO indication for radar ST. So that was a pivotal moment for us to lay that foundation. We saw a very robust gross margin expansion. So, you know, we're clicking on all cylinders relative to finding the efficiencies that we thought we could find across the business. And that translated into solid EBITDA growth as well. And the underlying volume was even better than we expected. Remember, we had to go through that kind of high volume, you Know, low value contract. And we were kind of thought flat to up a little bit. It was up 2%, you know. And the underline was up 3%. So, we think we're really well positioned all in all, you Now, and it was a really good strong quarter for us. I think maybe just two additional things. I mean, we saw a 53% improvement year-over-year in adjusted EBITDA, so a stronger online improvement. And I think with that, we also raised the guide. So I think that rounds out what Tony said. We felt quarter three was a strong quarter for us. So maybe on the point of NGS, it accelerated 29%. I think it may have been blended 26% or something like that in the first half. But the full year guide's guiding to greater than 25 for the full year. So maybe that reads like somewhat of a step down in Q4. Maybe give us some color, I guess, on how you're thinking about Q4, why not carry a higher rate forward? I get that it's more than 25%. How much of that is conservatism versus something you're seeing? It's just being prudent. It's being prudent, as you said, it was 26%, 26 percent 29 percent we just said we don't need to get out ahead of our skis at the end of the year it's going to be above 25 percent um so it's just us being prudent you know a day or two at the end of year makes a big difference so we're we don' t see anything in the underlying business that gives us pause comes a little tougher as well so there's a couple of factors but there's nothing here there's nothing systemic or underlying it's got it on the point of large panel volumes stepping up to more than 25%. I think it was more than 20% in Q2. What is driving that step up? How much is Pan Tracer Liquid playing a role? So I think there's multiple factors. First and foremost, it's driving. And I think historically, we've brought in a number of new products that are all large panel on the NGS side of things. This dates back to 2023, and we're really starting to see good continuous momentum there. So that's obviously a driver. I'll touch on liquid in a moment. We've continuously expanded our sales team and we spoke in the Q3 earnings that we've now increased the sales team to 160 people. So the more feet on the ground is helping to accelerate this. And we are seeing just within the community as well, a greater focus now on large panels versus targeted panels. So there is a bit of a trend starting to shift within the market and we're well positioned to take care of that. And then I think one of the biggest drivers is our Pantracer family. So this is our solution for solid tumor NGS, whereby we have Pantracer tissue, Pantraser liquid, Pant tracer tissue with HRD, and Pantracer Pro sort of wraps that around this. And we've actually found that this sort of bundled approach to the market has actually been very, very well received. It's very, very well-received and it's that combination, that category that's actually driving this outsized large panel growth, because these are all 500 plus gene sort of assays that we have out there. So it's really the combination of them. Certainly liquid is still a relatively small base, but as a percentage from a growth perspective, the highest growing assay that we have within the large panel. It just talks about the quality of the underlying revenue growth, right? Whether this is coming from the NGS and within the NGs, you have the large-panel growing a lot more faster, which basically is helping us going back to the first question that you had on the Q3 performance. So I think the quality has been really good. and maybe on pan tracer tissue before we move to liquid i think volumes doubled 2023 to 2024 maybe they nearly doubled again in 2025 how have those volumes in in aep been tracking in in 2026 so i'd say positively you haven't sort of disclosed it uh in in granular detail but i'll say to you it's well north of 50 percent uh obviously large numbers starting to play a role Yeah, and well north of 50%. And as we grow volume, we're certainly seeing improvement in AUP as well. And that's on the back of improved coverage that we're getting, et cetera. We spoke on our Q3 earnings call around numerous sort of wins on the commercial payer side of things. So that's helping as well in terms of bulk coverage. And with Pan, Tracer, Liquid, can you give us a sense, I guess, of how big the ordering base is today in where you're seeing the strongest early demand? So, again, in terms of we're exclusively focusing on the community, so obviously all the demand is coming out of the community at this stage. We definitely see generalist practices within the community making use of liquid more so with us than what we see in terms of any specialized practices that exist within the Community. So again, it speaks to the utility of our Pantracer family offering that we've got out there. And we're tracking how many Pantracer tissue physicians are actually using liquid, not only in a reflex option. Reflex is the easy button. We don't have tissue. We get a QNS TMP. But how many are actually doing it? We're actually using it as a practice. And we still have less than 30%. So there's still a lot of opportunity there for us to really penetrate our existing customer base of Pantracer tissue with liquid, but then also a lot opportunity in the markets where we actually haven't penetrated yet as well. And that's where I was going next with the Pantacer tissue penetration. I guess what's preventing that from being higher? Is it just time on task and kind of where you are in the launch? Yeah, I think it is. And it's just also the field coverage was another area. Again, we've always had one of the smallest sales teams out in the market, and we have been very disciplined in terms of how we've invested in sales resources as we've had new products come to market. And because we've got a smaller sales team, we've also had a smaller number of sales teams and we've almost always focused the sales team around where they call. So we give them very specific targets. So we're driving past potential customers to go from one target to the next, but because of the way we've targeted them, we've targeted them based on the biggest opportunity and the highest probability of winning, basically. So now as we've expanded our sales team, it's allowed us to call on more customers. That's driving the growth. As we said in our Q3 call, based onthe fact that we're expecting reimbursement on two new radar indications, one by the end of this year and one by mid-next year, we'll expand the team again. That's going to give us greater coverage and that's going help to drive growth of the Pantracer tissue family and NGS on the game side of things as well. Do you have sense for what percentage, I guess, of liquid orders are coming from physicians who are new to liquid versus competitive wins? Not really. It's a difficult one to quantify because, I mean, it's the practice level, it's a positional level, etc. I still I'll answer the question a little differently I think the in the community the use of liquid is still maturing right sort of how it's very well understood around the qns tmp where I don't have tissue I can't get a result on solid let me use liquid but as a liquid first strategy in the committee it's still maturi when you do get a competitive when what is it that usually tips that physician or account, I guess, to Neo? Absolutely. I think this is where there is clear evidence, and it's really the portfolio play. So maybe just to talk through the portfolio, obviously we have a solution at the diagnosis side of things, the therapy selection and MRD, and that's for both heme cancers and solid tumor cancers. Now, today, the way the guidelines are structured, every single cancer journey starts with a primary diagnosis. that's where every cancer journey starts we do primary diagnosis we get access to the patients at the primary diagnosis stage and the strategy is then to link the fact that we had access to the patient then to pull through the other testing that needs to happen and let me let me talk about a little bit of a workflow that could happen there so a patient comes in and there is a primary diagnosis request and we identify that they've got non-small cell lung cancer we would have done that test and you've probably done some PD-L1, the next recommended action would be to run the Pantracer family. That would be the next thing to do because you want to actually understand what specific markers you would do. If you had enough tissue, whether this is a lung cancer, you would actually run solid tumor is what we would do, but because it's lung, often there's not, or you would get a QNSTMP, we would then use liquid as an alternative. So that would then identify exactly what markers have expressed, et cetera, and that'll give the treating physician an option to think about what treatment to put my patient on but at the same time if that test one of the tests came back tmb high that would indicate that this patient would be a good candidate for io therapy that's what tmb is actually used for as soon as we see this trigger of uh io is tmb as high strong candidate for yo therapy reach out to the physician say would you like us to run radar st because we have we have io coverage we still have your sample we actually have extracted the DNA to run the test, would you like us to actually run the radar ST-assay? So where we are winning, it's really on that continuum of care, that we can actually take a patient from that primary diagnosis all the way through to surveillance from an MRD perspective. It's a breakthrough portfolio. How is physician demand for liquid, I guess, tracking compared to demand for tissue whenever you launch that? I guess you said it's less mature, but how would you compare them? I'd say it's not tracking at the same rate. It's probably tracking at a slightly slower rate. And again, it comes back to the physicians in the community are still very much guideline-driven. That's kind of, you know, you've got a physician seeing a patient every 15 or 20 minutes, walking from one cubicle to the next. And as they're walking out the cubicle, they're quickly scanning through their iPad to see, okay, who am I seeing now? What results have come in? It's very quick before they walk into the next cubicle. And what they want is, they want certainty when they treat their patient and they lean towards the guidelines. And today, the guidelines really speak to tissue as the primary standard. And that's why, in my opinion, we're seeing a slow reduction of liquid burst testing in the community. It's catching up, but it's still slower. And as a result, we see our ramp of liquid relative to Pantracer tissue to be slightly slower. And Warren, I think it's also fair, Mason, it's also part of our strategy, right? When we launch a new product, you know, it is not our intent to try and change that physician's practice mindset overnight, right, like we look at Pantracer liquid as a contributor to the Pantraser family, just like we looked at Pantsracer pros, a contributor to the Pantreser family. As long as we see the robust growth growing there, we can then accept the adoption curves that'll happen in the community over time that then gives us liquid growth long in the future. So we've always maintained that liquid would be a contributor more as a halo effect to Pantracer family. Liquid itself would become more of a driver in the 28, 29, as it starts to ramp up as well. So it's not like we're out telling our field force, liquid, liquid liquid. We're out there at Pantracer family, liquid is a part of, right? Right. There's other sort of limitations with a liquid-only strategy. There's certain other testing that you would want, so biomarker testing that your want that you wouldn't be able to get out of liquid. Like Chlorine 18 is an example. You'd have to send a solid tumor sample in anyway to run Chloride 18 and other indications. So I think physicians are still figuring that out in the community. How do I send liquid? Where do I get some of the other biomarkers testing done, et cetera? Whereas if I can stick to solid, I get all of that done off one song, one requisition. And, Warren, I think it may have been you said that large panel penetration is like, what, 35%, 40% in the community, something like that. What share, maybe what share you have today is a little bit tough, but where do you think is a realistic target for NEO? I would break that down in two ways. On the heme side of things, I Think we're a large panel heme. We're the market leader today. Yet we're still growing that business at a similar rate to, not the same rate, but a very similar rate to what we see on Solid Tumor. I do think we can take, we're going to continue to take share there based on our positioning. And I see north of 30, certainly on the heme side. I would say we probably have five share in Solid Trumor today, and I expect we will double that at least. And I'll add to that. I think this is basically kind of also the other piece of this is on the NGS durability, right? When we say that, okay, the penetration is so low, and given the fact that $250 million on the NGS and a sizable portion of that revenue is coming from the CGP, you have a lot of room to grow, right, so I think that could be another angle to see from that perspective, that instead of we having a target that, we need to be at 60, 65, 70%, it basically provides a long runway for us. Right. I mean, that would imply what 60% of patients are getting their selection test. Exactly. Warren, on the upgraded neocomprehensive heme panel, I think that was introduced late in Q3. How much of an impact do you think that upgrade could have on adoption? And how quickly, I guess, does the benefit of an upgrade like that start to show up in volumes? Yeah, so that upgrade was important because it really differentiates us. So maybe just to talk about what we did. So we added UBA1, which is a new requirement basically for detecting Vexus syndrome. So we've added that, which makes us unique. I think there's only one other provider of the solution, and they're not a mainstream provider in the country. We reduced our turnaround time from what was 14 days to now 8 to 10 days. So we took a significant amount of time out of the turnaround time, and then we reduced the VAP, the variable length frequency, which is a proxy for sensitivity. We reduced it from 5% to 3%. So basically, we provided a much more sensitive assay, which was much more comprehensive at a shorter turnaround time. That's ultimately what we had done through this upgrade. It was very late in Q3. So we have seen a very strong positive feedback from customers already. Very much so. So I expect this to be a key driver of growth for us in 2027. Got it. How do NGS order transit accounts where you have bi-directional interfaces compared to where you don't? There is no question that business in general, and it's not unique to NGS. We see it from the MRD side of things. We even see it on the diagnosis side of thing. The simplicity that a bidirectional interface brings a treating physician, it's an easy button. You see everything represented. You see that you're looking at the patient. You can requisition the test within the patient record. The results flow back into the patient records. You typically have alerts. You're able to see the patient history within your EMR. So there's no question that when you have a bidirezional interface in place, it drives higher utilization of your tests. and and this is also where we also install what we call care pathways and that's exactly the workflow okay this patient was positive from a non-small cell lung cancer let's automatically now run ngs testing let's dramatically now run mrd testing that can happen automatically without a physician actually getting involved and i think it's these types of simplicities and convenience that drives the higher utilization when you have the the interfaces in place right and maybe pivoting to radar i think you talked about volumes improving month over month since the io launch where do ordering physicians stand today repeat orders um any insight you can give us there um yeah we have a broad perspective of people that are i i would say i would consider them as trialing they've ordered five or less tests from us and and others that have ordered 50 and more tests from us so we have bookends yeah obviously the the strategy is to move every single position that is in the trialing phase less than five up that continuum but what you typically want what most physicians are saying is they want to experience the whole experience and for them it's understand that for radar st and other any mrd essay the first time point first setup and time point is roughly 30 days that's your that's your initial exome set up in your first time point takes 30 days and then you're typically running a follow-up time point somewhere between 8 and 12 weeks depending on the indication hitting on the position so you're kind of looking at three to four months before that position has a complete experience around what neo looks like just that initial setup follow-uptime point so we saw a nice uptake with io um and and we're seeing substantially substantially increase in physicians that are trialing um and we're not pushing them through based on a good experience so um again we're bullish in terms of how we think radar st will develop in 2027 based on io but also in terms of other covered indications that we anticipate later this year and the first half of next year and i think you said that you take orders that are pending indications but you're not actively promoting them i guess how is your oncology reps or how are your oncologist splitting their time across the indications that that are approved today how much of a focus is io yeah meaningful because um so again you're absolutely right that's our strategy we'll accept we obviously actively marketing for the three indications that we have coverage on and we believe that that represents about 20% of the TAM today, so we feel about a 20 billion TAM, and the three indications we have covers about 20%. The two additional indications that are pending coverage will take us to 40% of the TEM, so a very attractive position. Today, actively marketing for the three that we've got, but accepting orders for the other two as well in anticipation of reimbursement. So, today, I would say the lion's share of our sales team is focused on IO, just because of the breadth of that. That covers many, many different indications you can use IO on, and it becomes an easier value proposition to portray to the physician. But at the same time, they're also talking about the sort of continuum of care perspective. And again, you've used us for therapy selection. In many cases, your next step would be great RST. we've already done the DNA extraction, we can automatically run your radar ST. So they sell earlier in the workflow as well because that's an easier way to tie the positioning. And I guess on future indications, how are you deciding what goes on radar ST versus what gets dedicated to the next generation assay? I think the simple way to answer that is just around sensitivity requirements so shedding levels so as soon as something um requires very very low levels of detection below that sort of one ppm we're probably going to move that on to next gen um those other indications which are not as sensitive um we will probably stick them on radar because we'll have a more competitive price point on on the radar st assay than we will have on on a genomics assay but that's the separation but i also maybe just want to plug the point here that RadarST is a very, very competitive assay. We have resulted numerous patients at one ppm. Even though it's an exome-based assay, we've already resulted numerous patients at 1 ppm, so it's a very good assay but we do feel for things like melanoma as an example, we're going to need a whole genomic assay right. You could also see over time, as Warren said, you know, lower shedding, obviously, we go to next gen, but we're going to continue to invest in R&D RST. As he said, it's a great test in its own right. I think you might see some of the emphasis shift from just trying to get broad-based indications, because once we secure the next two, we feel that we'll be pretty well covered from a market PAM perspective. But you can see us probably start to emphasize more emphasis around the commercial payer community, right, and investing a part of the r d budget driving that commercial utilization piece um because you know i i don't know but you may you know to me you start knocking on 50 of a tam i think yeah you know you can worry less about that piece and now let's get the people to pay for it right especially a tam as big as is the one for mrd yeah yeah um from a timeline perspective i think you said one decision potentially by year end the other by mid 2027 are those still on track where they sit in the process today very much on track okay uh we're still you know confident uh and what we stated to have the the one by the close of this year and that will certainly well position us going into uh 2027 uh and the others on track by for uh mid of next year yeah what does the submission pipeline look beyond those indications i know that you were talking about kind of the tan you'll have access to but just curious yeah we're not going to get too specific but really appreciate your your effort there um you know we will continue to invest in both radar and next gen yeah got it um i think on the q4 call last year you guys talked about 75 percent community oncologists in in 2025 ordered five or more neo tests how's that trended this year uh we see us that's that's ticked up slightly um it's it's for a data point we should it's ticked up slightly so we're we're happy and we attribute that uptick to the fact that we've broadened our coverage at the end of the day there's a very clear uh correlation between physicians that are using neo versus where our sales people are calling i know it sounds that seems like a obvious statement but as we've expanded our sales team we've seen that that sort of penetration of physicians using five or more increase further in line with the investments from the sales team perspective so we feel that those investments from a commercial perspective are paying dividends got it um maybe jumping around a little bit uh i'll check you said volume and asp should each track to back i guess to to mid single digits next year once you kind of lap that contract i guess with the clinical business grown 13 percent so far this year it seems like you've got multiple drivers um still pretty early in their ramp is it fair to call mid-single digits on on at least volume somewhat of a floor next year yeah my my short answer is yes okay right uh of course uh there have been some volume and the aup dynamics in the last couple of years and as they stabilize 27 when we call out the single digits for the clinical revenue that can be termed as like a base case and then of course we'll see as to how we guide the full 2027 in our q4 call got it and from an ngs perspective you're lapping 26 29 comps i guess how do you weigh those comps against you know maybe a full year of Pantracer Liquid coverage, Pantracer Pro, the Heme upgrade, EMR integrations. I guess hard to get guidance right now, obviously. But I mean, how are you feeling about the NGS business heading into next year? No, we are very happy to see the growth momentum in the NGs portfolio, because there has been this debate, like in the early part of this year, we always will get a question on how durable the NGS growth is. Now we are putting that growth quarter over quarter. So I think that debate is more or less settling now. Now it's a question, okay, how long would this growth be? And, of course, we are basically kind of pointing to the indicators that there is a lot of room left in the tank. And the last piece is around the guidance. So, of coarse, there will be a little bit of a tougher compare, as you are pointing out, versus the 25 in 2026. 27 will have slightly tougher compares but of course we'll have the benefit of the full year of our new product launches as you call it out so we don't feel that uh there will be any uh slow down uh in the growth momentum and we feel very confident about it from a rep standpoint how should we think about the pace and size of additions yeah i would say we'll give some more granularity on that specifically earlier in in the new year uh but we will definitely continue our sort of philosophy of hiring a head of new product launches or new indications becoming available that's a strategy that's worked well for us it allows us to be very disciplined in terms of how we invest from a a commercial perspective we as we've said we expect one additional indication this year and another one for radar st and another one in in the first half of next year so we will be investing um in now and in the the first quarter uh and probably as new products come to market in the latter part of next year we'll probably be investing further but we'll provide more color in that in the new year got it and maybe pivoting back trend pantracer pro real quick how many add-on tests are you typically seeing per order and i guess what does revenue per order maybe look like compared to you know like pantracer tissue on its on its own so um great question it ranges in some cases it can be as little as one we've had an extreme case where it's been nine uh but you're averaging somewhere between three and four uh and and basically at that average it's increasing the average order value by a little north of twelve hundred dollars okay for the non-clinical business Pharma has continued to face headwinds. Small piece of the business now, but maybe just talk about, you know, the confidence in maybe that business at least nearing a bottom in non-clinical returning to growth. Yeah, my confidence level hasn't changed. You know, I think non-cinical in totality certainly can be a return to growth story for 2027. I would say it would be non-material though, Mason, I think it's a long-term strategy for us. You know, we like what we can do in the molecular side of that pharma business, but continuing this to pursue volume on kind of the high volume, low value added part of that form of business is not a place we want to be over time, you know, but the margins, cause on that side, that margins are so low. It's just not worth the effort. Bluntly, you Know, we'd rather see our efforts focus and doubling down on NGS and MRD, and that's inclusive of the, of the pharma space as well. So non-clinical, we believe absolutely return to growth pharma we'd like to continue to really focus on only the the molecular piece drive that really really hard and you know because the other side is just make it by a few miss it by few at the gross margin level in ebita it it's just not there i'd rather focus on the 93 of the growth yeah no that makes sense and abhishek maybe could you just walk us through the puts and takes on gross margin and in ebitda you've got NGS revenue, you know, margin accretive, you've got radar volumes ramping, which are probably dilutive at this point, the Nova Seek X transition, maybe just walk us through the things we should be considering moving forward. No, absolutely. On the gross margin, I see that there are multiple levers for continue to expand the gross margin in 27 and beyond. You've rightly called out the NGS growth is basically a high margin business for us. And it's growing at a much faster pace as compared to the rest of the portfolio. The second one is, of course, our AUP growth. So AUP Growth, we do have pricing increases as well as the commercial wins, the coverage and the policy, which will help us drive the gross margins. And the third piece we have always called out, the Lab of the Future initiative. And within that initiative, there are six different tracks, and one track is the NovaSeqX transition. and we will basically have our heme portfolio which is a majority portion of our ngs revenue actually move from the nova seek 6000 to nova seek x that will help us drive the gross margin expansion so we have seen like well over 150 basis points of gross margin expansion in 2026 will provide more color as to how the expansion should look like in 2027 but those are the levers for driving the margin expansion. But at the same time, we just need to keep in mind the radar as we kind of start to drive the volumes because our focus in 27 for radar is going to be acquiring the patients. I think that is going to be one of the pieces we would want to like now start to leverage if we were to get, say, a 40% of the MRD time as to how we can start to acquire the patients and then we are able to kind of get paid for those tests. so that will become i would say a little bit of a headwind in 2027 and the other piece is the pama so we have basically called out that as another piece so those are the two pieces that probably will offset some portions of the gross margin expansion but absolutely we still feel that we will be able to expand our gross margins in 20 27 which will also kind of then reflect in order, just a little bit of margin expansion. And I think you maybe plan on having an investor day next year. Should we expect that update to include multi-year targets? I would say we will basically provide a little but more color on the construct and the guardrails, right? Not necessarily the full P&L or those kind of details, But we'll basically have some key pieces of information that basically drives the valuation for the company. So absolutely, we are still kind of deliberating internally what all would make sense. And we'll come back when we will basically have the full plan in place for the investor day. Got it. And then I guess as we wrap up, I feel like I have to ask something like this. But Warren, you're taking over as CEO. Is there anything that you'll prioritize differently? within the clinical business or how you're thinking about the strategy moving forward. Yeah, so actually today's my four-year anniversary with NeurGenome. So I say that only because I've seen a lot of the history that's unfolded over the last four years. And I'll say that under Tony's leadership and the rest of the executive leadership team sort of played a pretty fundamental role in developing the strategy. So I feel the strategy that we have today, pure play oncology, focus on the community where 80% of patients are served, continuum of care strategy from diagnosis, therapy selection and MRD for both heme and solid tumor with a right to win because we see the patient for primary diagnosis. So we see The Patient First as a compelling strategy, 100% behind the strategy. Really where the focus is, is how do we extract more value faster? that's where that's where my intention is going to lie and you can expect that focus to be around MRD and NGS got it all right well unless we have any questions we can wrap there thanks guys thank you appreciate it thank you

Company
NEOGENOMICS INC
Keywords
NEOGENOMICS INC